lung cancer

News

NICE backs drugs for lymphoma and lung cancer from Roche and...

NICE has recommended NHS funding for a duo of cancer drugs, giving final guidance on new options for certain patients with follicular lymphoma and lung cancer.

News

Sanofi and Regeneron eye challenge to Merck & Co in first li...

Sanofi and Regeneron could mount a challenge to Merck & Co’s Keytruda in untreated advanced lung cancer with their cancer immunotherapy latecomer Libtayo following new phase 3 results.

News

Tagrisso trial halted early after ‘overwhelming’ efficacy

A phase III trial for AstraZeneca’s lung cancer drug Tagrisso (osimertinib) will be unblinded early after strong results.

News

FDA approves AZ Imfinzi in new lung cancer use

AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, and it stopped a trial of its Farxiga after showing “overwhelming efficacy” in chronic ki

News

AZ's immunotherapy combo fails in phase 3 lung cancer trial

AstraZeneca’s Imfinzi plus standard chemo improves overall survival in untreated extensive-stage small cell lung cancer – but a combination therapy involving another immunotherapy does not,

Views & Analysis

Staying on the cutting edge of oncology advances

Rapidly-changing treatment landscapes in diseases like lung cancer pose challenges for medical education providers, who need to be more adaptable than ever.

NICE backs drugs for lymphoma and lung cancer from Roche and...

Sanofi and Regeneron eye challenge to Merck & Co in first li...

Tagrisso trial halted early after ‘overwhelming’ efficacy

FDA approves AZ Imfinzi in new lung cancer use

AZ's immunotherapy combo fails in phase 3 lung cancer trial

Staying on the cutting edge of oncology advances

AZ's gMG drug Klygefa nears EU approval

Discover a new era of healthcare panel engagement: Grounded ...

lung cancer

Editor's Picks